Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15

Benzinga Newsdesk www.benzinga.com Neutral 61.5%

Neg 0% Neu 61.5% Pos 0%

Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating and announces Price Target of $15.